Intel Corporation has extended its lead in the high-end server segment, setting new standards in virtualization performance with the launch of seven 45 nanometer-manufactured Intel Xeon Processor 7400 Series products.
The intracellular target for CALAA-02 is HIF-2alpha, or Hypoxia Inducible Factor-2 alpha. HIF-2alpha is overexpressed in a number of solid tumors and is critical for many aspects of tumorigenesis, such as metastasis, angiogenesis, tumor cell proliferation, and tumor response to radiation.
Veeco Instruments Inc. announced today that it has become a charter member in the CPV Consortium, a global industry organization that supports the development and long-term success of the concentrator photovoltaics industry, with the goal of providing a low-cost, reliable source of renewable energy.
SEMI urges Congress to immediately reinstate the R+D tax credit and to pass a long-term extension of the investment tax credit (ITC) for solar energy. The R+D tax credit expired on December 31, 2007 and the solar energy ITC is set to expire at the end of the year.
By providing a choice of analog or digital absolute angular-rate outputs, the LY530AL MEMS gyroscope from STMicroelectronics enhances design flexibility, eases integration and saves external components.
LDK Solar Co., a leading manufacturer of multicrystalline solar wafers, announced today that it has signed an 11-year processing service agreement to process upgraded metallurgical grade solar-grade silicon provided by Germany-based Q-Cells AG into wafers.
NanoHorizons Inc., a leader in the creation of nanoscale antimicrobial performance additives for the textile, health care, and coatings and plastics industries, will participate in The Green Event Conference and Expo in New York City, September 18-19.
MonoSol Rx, a drug delivery company specializing in quick dissolving thin film pharmaceutical products, today announced that it has been granted U.S. patent No. 7,425,292 from the United States Patent and Trademark Office (USPTO).
Calando Pharmaceuticals, Inc., a majority owned subsidiary of Arrowhead Research Corporation, announced today that it has initiated a Phase II clinical trial in the United States evaluating the safety and efficacy of its drug candidate, IT-101 in patients with platinum-sensitive ovarian cancer.